Research presented by LRA, LT, and collaborators will address some of the most significant challenges in lupus, including reducing barriers to clinical trial participation, improving trial design and outcome assessment, evaluating molecular signatures associated with disease severity and treatment response,…
Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds. These mutations are widespread in immune cells called neutrophils. Other…
A phase 1/2 study evaluates a CAR T-cell therapy engineered to switch off PD-1 and TIGIT in patients with relapsed or refractory large B-cell lymphoma. Dual Knockdown CAR T-Cell Therapy Linked to High Response Rates in R/R LBCL Anbalcabtagene autoleucel…
LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds. These mutations are widespread in immune cells…
Lupus affects around 1.5 million Americans, and nine out of ten people diagnosed with the disease are female. The root cause of lupus is unknown, and there is no cure. New research published in Nature shows that lupus patients have mutated…
(Aging Untold) — On this episode of Aging Untold, we break down the daily realities of living with lupus, shedding light on the unpredictable fatigue, pain and invisible burdens of this autoimmune condition. We explore the complex choices surrounding feeding tubes,…
A histology showing the ankle joint of a mouse four days after receiving the new antibody treatment, V11 sFc. Newswise — Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to…
May 23, 2023, 08:53 ET People with lupus have played a key role in the development of the Lupus Nexus and will continue to be at the core of this effort through their participation in the Lupus Landmark Study. Their engagement will generate…
CAR-T therapy is a powerful treatment for relapsed or refractory multiple myeloma, a blood cancer that can be difficult to treat. In multiple myeloma, abnormal plasma cells multiply uncontrollably, crowd out healthy blood cells, and produce dysfunctional proteins, which can…
See all articles from Blog: ASTCT Update Growing evidence suggests they soon may have a similarly profound impact on autoimmune and other immunological disorders. To help clinicians navigate these developments, the American Society for Transplantation and Cellular Therapy (ASTCT) and…
Lupus: diagnosis and symptoms, new drugs and CAR-T cell therapy for lupus, lupus nephritis and living with the disease.
An article joins this feed when it matches these terms. Each one is also a search of its own.